118th Congress · HOUSE BILLBILL

H.R. 7188Shandra Eisenga Human Cell and Tissue Product Safety Act

To require the Secretary of Health and Human Services to conduct a national, evidence-based education campaign to increase public and health care provider awareness regarding the potential risks and benefits of human cell and tissue products transplants, and for other purposes.

Health
Introduced Feb 1, 2024
Last action Dec 17, 2024
Pipeline · Bill → Law
Step 1
Introduced
Feb 1, 2024
Step 2
Referred
Feb 2, 2024
E&C
Step 3
Committee
Sep 18, 2024
Reported out
Step 4
House floor
Step 5
Senate
Dec 17, 2024
Step 6
Resolve Changes
Step 7
Signed
SummaryCRS Summary

This bill requires federal agencies to update guidance, regulations, and educational materials about transplants involving human cell and tissue products, particularly with respect to safety and eligibility standards. Specifically, the Department of Health and Human Services must support the development of educational materials for health care providers about issues relating to organ, tissue, and eye donations; screening tests; and other aspects of donations. The Food and Drug Administration (FDA) must review current guidance on donor eligibility and, if appropriate, update it with information on how to reduce the spread of tuberculosis or sepsis in association with donations. The FDA must...

Provisions · 6 sectionsEngrossed in House
Timeline · 15 actions
Dec 17, 2024
Received in the Senate.
Dec 16, 2024
Mr. Bucshon moved to suspend the rules and pass the bill, as amended.
Dec 16, 2024
Considered under suspension of the rules.
Dec 16, 2024
DEBATE - The House proceeded with forty minutes of debate on H.R. 7188.
Dec 16, 2024
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
Dec 16, 2024
Motion to reconsider laid on the table Agreed to without objection.
Nov 22, 2024
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-766.
Nov 22, 2024
Placed on the Union Calendar, Calendar No. 632.
Sep 18, 2024
Committee Consideration and Mark-up Session Held
Sep 18, 2024
Ordered to be Reported (Amended) by the Yeas and Nays: 40 - 0.
May 16, 2024
Subcommittee Consideration and Mark-up Session Held
May 16, 2024
Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 27 - 0.
Feb 2, 2024
Referred to the Subcommittee on Health.
Feb 1, 2024
Introduced in House
Feb 1, 2024
Referred to the House Committee on Energy and Commerce.